Estimating the direct and indirect costs associated with Parkinson's disease.
Parkinson's disease (PD) is a progressive, neurodegenerative disorder whose symptoms and manifestations greatly deteriorate the health, functional status and quality of life of patients, has severe consequences on their families and caregivers and supposes a challenge for the healthcare system and society. The aim of this paper is to comprehensively and descriptively review studies on the economic impact of the disease and interventions, analyzing major contributing factors to direct and indirect costs in PD. Cost-of-illness studies have shown that costs of PD are high, mainly due to drug, hospitalization and productivity loss, and tend to increase as the disease progresses. Studies on PD treatment have suggested that therapies for advanced PD (levodopa/carbidopa intestinal gel and apomorphine) and surgical procedures are cost-effective and cost saving, despite their high expenditures; however, further research such as on the economic impact of non-motor manifestations or on the cost-effectiveness of non-medical interventions is still needed.
a National Center of Epidemiology and CIBERNED , Carlos III Institute of Health , Madrid , Spain.
Carmen
C
Rodríguez-Blázquez
b National School of Public Health and REDISSEC , Carlos III Institute of Health , Madrid , Spain.
Maria João
MJ
Forjaz
c Outcomes'10 , Castellón de la Plana , Spain.
Luis
L
Lizán
c Outcomes'10 , Castellón de la Plana , Spain.
Silvia
S
Paz
a National Center of Epidemiology and CIBERNED , Carlos III Institute of Health , Madrid , Spain.
Pablo
P
Martínez-Martín
D000978:Antiparkinson Agents / Q000191:economics / Q000627:therapeutic use*; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D018450:Disease Progression; D016527:Drug Costs; D006760:Hospitalization / Q000191:economics; D006801:Humans; D010300:Parkinson Disease / Q000191:economics / Q000503:physiopathology / Q000628:therapy*; D011788:Quality of Life
D000978:Antiparkinson Agents
Parkinson’s disease; QALYs; cost of illness; cost–effectiveness; economic evaluation